Description of the medicine: Lipostabil (Lipostabil)
LIPOSTABIL (Lipostabil) *.
A complex preparation produced in capsules (fort) containing unsaturated fatty acids (linoleic, linolenic, oleic; total in a capsule is 300 mg) and 7- (b-hydroxyethyl) -theophylline (50 mg in a capsule), as well as in ampoules for intravenous injections containing the same acids in an amount of 500 mg, pyridoxine hydrochloride 4 mg, nicotinic acid 2 mg; adenosine 5-monophosphate (AMP) 2 mg.
The hypolipidemic effect of the drug is due to the action of unsaturated fatty acids (see Linetol) and other components. The presence of theophylline derivative in capsules can contribute to the anti-aggregation effect, and the content of nicotinic acid and other components in the amulets has a lipid-lowering effect, although the dose of nicotinic acid in the preparation (2 mg per ampoule) is small.
Recommended for use in hypercholesterolemia and hypertriglyceridemia, atherosclerosis, disorders of coronary, cerebral and peripheral circulation, nephrotic syndrome and other diseases associated with hyperlipoproteinemia.
Assign 2 capsules (do not chew) into adults 3 times a day before meals (with a small amount of water). The course of treatment is 1-6 months or more.
10–20 ml (in an ampoule of 10 ml) are injected (slowly) into a vein for 2–4 weeks, then they are transferred to maintenance therapy (by mouth, 1–2 capsules 3 times a day).
The drug is usually well tolerated. Intravenously administered without additional dilution. Dilution with sodium chloride solutions is not allowed. Intramuscular injections are painful.
Method of release: in capsules in a package of 50 pieces; in ampoules of 10 ml in a package of 5 ampoules.
Storage: in a cool, dry (capsule) place.